Pharmacokinetic analysis of LADDER trial shows sustained efficacy of ranibizumab refillable implant

A pharmacokinetic analysis of the LADDER trial indicates that the Port Delivery System filled with the higher 100 mg/mL dose provides continuous release of ranibizumab through at least 16 months.
“Serum concentrations were within the range achieved with monthly intravitreal injections,” Peter Campochiaro, MD, said at the virtual Association for Research in Vision and Ophthalmology meeting.
The Port Delivery System (PDS, Genentech) is a permanent, refillable implant that is surgically inserted through a small incision in the sclera and pars plana, allowing continuous delivery of

Full Story →